New India : HL October 19, 2026
India must move towards a healthcare system that combines affordable treatment with measurable improvements in patient outcomes, according to Dr Rahul Bhargava, Principal Director and Chief of Hematology, Hemato-Oncology and Bone Marrow Transplant.
In his recent remarks on the future of healthcare in India, Dr Bhargava emphasised that lowering treatment costs and ensuring appropriate price controls are important steps towards improving access to medical care. However, he stressed that affordability alone cannot define the success of the healthcare system. The ultimate objective must be to help patients live longer, experience less suffering and achieve a better quality of life.
His observations highlight the need for a more transparent, evidence-based and accountable approach to cancer and blood disorder treatment, where healthcare institutions are assessed not only on the availability and cost of treatment but also on the outcomes they deliver.
Affordable Treatment Must Deliver Better Outcomes
India has made efforts to improve access to healthcare, but the next phase of progress must focus equally on treatment effectiveness, according to Dr Bhargava.
He noted that reducing medicine prices and introducing appropriate price caps can make treatment more accessible, particularly in a country where the cost of prolonged medical care can place considerable pressure on patients and their families.
Nevertheless, affordable treatment must translate into meaningful clinical benefits. Patients and their families need to know whether treatment is improving survival, reducing complications and helping individuals return to a better quality of life.
This is particularly important in oncology and hematology, where treatment outcomes can vary depending on the disease, its stage, the patient’s overall condition and the complexity of the required intervention.
Cancer and Blood Disorder Care Needs Standardised Outcome Reporting
Dr Bhargava called for a mandatory and standardised framework through which institutions treating cancer and blood disorders report their clinical outcomes.
Such a framework, he argued, should be supported by independent audits to improve the reliability and transparency of the information being reported.
A comprehensive outcome-reporting system could include several key indicators:
- Patient survival rates and long-term treatment outcomes.
- Treatment-related mortality and complications.
- Quality of life during and after treatment.
- Treatment completion rates and interruptions in care.
- Access to supportive care and newer treatment options.
- Factors affecting diagnosis, treatment decisions and continuity of care.
Standardised reporting would help healthcare institutions identify weaknesses, compare performance more meaningfully and develop targeted strategies to improve patient care.
Delayed Diagnosis and Interrupted Treatment Remain Important Concerns
The quality of cancer care depends on several interconnected factors, not merely the price of medicines or procedures.
Dr Bhargava highlighted the need to examine possible gaps associated with delayed diagnosis, interruptions in treatment, limited access to supportive care, shortages of trained healthcare professionals and uncertainty in clinical decision-making.
Financial constraints can also prevent patients from completing prescribed treatment or accessing appropriate medical services.
Identifying these barriers is essential to developing solutions that address the actual needs of patients. The reasons behind poor outcomes may differ across diseases, hospitals and patient groups, making reliable, disease-specific data particularly important.
Independent Audits Can Strengthen Accountability
According to Dr Bhargava’s proposed approach, healthcare institutions should be evaluated through credible reporting mechanisms that include independent verification and appropriate patient follow-up.
Reliable data is essential for understanding whether a treatment programme is achieving its intended objectives. Selective reporting or incomplete follow-up can create an inaccurate picture of clinical performance.
At the same time, comparisons between hospitals must account for differences in disease severity, patient risk and treatment complexity. Institutions treating patients with more advanced or complicated conditions should not be judged without considering these factors.
A fair assessment system would therefore need to use standardised indicators and appropriate risk adjustment to ensure that comparisons reflect genuine differences in performance.
Transparency Should Encourage Continuous Improvement
Dr Bhargava emphasised that transparency should not be viewed simply as a mechanism for identifying shortcomings. It should also help institutions learn from one another and improve the quality of care they provide.
Consistent reporting can help hospitals recognise recurring problems, identify effective practices and introduce corrective measures. Independent verification can further strengthen public confidence in the information being shared.
A culture of accountability would encourage healthcare providers to acknowledge gaps openly and use evidence to address them rather than relying solely on claims about affordability or treatment availability.
India Needs Its Own Reliable Clinical Data
International clinical outcomes can provide useful benchmarks for assessing progress in cancer and blood disorder treatment. However, India also needs robust domestic data that reflects its own patient population and healthcare environment.
Differences in the timing of diagnosis, access to treatment, availability of specialists and continuity of medical care can influence outcomes. Generating reliable Indian data would help policymakers and healthcare institutions develop interventions suited to the country’s needs.
Such evidence could also support better resource allocation, more informed clinical decisions and the identification of areas where additional investment is required.
Measuring Healthcare Success Beyond Cost
Looking ahead, the broader challenge for India’s healthcare system will be to assess progress through tangible improvements in patients’ lives.
Lower treatment costs remain an important objective, but they must be accompanied by better survival, fewer preventable complications, improved quality of life and greater continuity of care.
Dr Bhargava’s message places patient outcomes at the centre of healthcare accountability. It calls for a system in which every rupee spent on treatment is assessed in terms of the benefits it delivers, supported by credible evidence and transparent reporting.
The way forward, therefore, lies in combining affordability with measurable clinical effectiveness. Strengthening outcome reporting, independent audits and India-specific evidence could help healthcare institutions identify gaps and work towards better results for patients with cancer and blood disorders.
